Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Increase in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a significant growth in short interest during the month of October. As of October 30th, there was short interest totaling 1,115,310 shares, a growth of 160.9% from the October 15th total of 427,404 shares. Approximately 3.7% of the company’s shares are short sold. Based on an average daily volume of 15,911,284 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Senti Biosciences Stock Performance

NASDAQ:SNTI traded down $0.00 during trading hours on Friday, hitting $0.14. The stock had a trading volume of 25,585 shares, compared to its average volume of 1,192,043. Senti Biosciences has a one year low of $0.14 and a one year high of $2.88. The company has a market cap of $4.52 million, a price-to-earnings ratio of -0.08 and a beta of 2.31. The business’s 50 day moving average is $0.26 and its 200-day moving average is $0.68.

Senti Biosciences (NASDAQ:SNTI) last posted its earnings results on Friday, August 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.08). The business had revenue of $0.02 million for the quarter.

About Senti Biosciences

Senti Biosciences, Inc. is a biotechnology company developing gene and cell therapies for cancer and other serious diseases. The company’s technology is based on synthetic biology, including programmable gene circuits designed to help engineered immune cells recognize disease-associated targets, respond to specific biological signals and limit activity in healthy tissue. Senti Biosciences applies its platform to the development of engineered cell therapies, including chimeric antigen receptor natural killer (CAR-NK) and other immune-cell programs.